Bristol-Myers Squibb Company ranks third among the 10 Best Pharma Stocks to Buy According to Billionaires. The company is undergoing strategic changes amid market shifts, including divesting its 60% stake in a China joint venture to align with industry trends.

This divestiture is part of a $2.5 billion restructuring plan to enhance efficiency and cut costs, with an expected $2 billion in annual savings by 2027. Workforce reductions are planned, with 282 layoffs scheduled in New Jersey, aiming for a total of $3.5 billion in savings from staff cuts and operational enhancements.

Financially, Bristol-Myers Squibb Company will report Q3 2025 results on October 30, with analysts forecasting earnings of $1.65 per share. The company also reaffirmed shareholder returns by declaring a quarterly dividend of $0.62 per share on September 17.

While Bristol-Myers Squibb Company shows investment potential, some AI stocks may offer greater upside with lower risk. For an undervalued AI stock poised to benefit from current trends, explore a free report on the best short-term AI stock.

Read more at Yahoo Finance: Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment